Business Wire

Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both Benchmarks

19.5.2026 07:00:00 CEST | Business Wire | Press Release

Share

Shufti has been named a Leader in both the Age Verification and Age Estimation categories of Liminal’s 2026 Index Report, receiving an Exceptional rating for Market Presence across both.

Liminal, an actionable intelligence firm, evaluates identity verification vendors across Product Execution, Strategy, and Market Presence, assessing scalability, accuracy, fraud resistance, innovation, and user experience.

Out of 189 vendors assessed in the Age Verification Index, only 17 achieved Leader status. Shufti was among them and exceeded the leadership threshold with a 64% Product Execution score and a 92% Strategy score.

In Age Estimation, Shufti again ranked among 17 Leaders from 80 evaluated vendors, exceeding leadership thresholds across core evaluation pillars, alongside an Exceptional Market Presence rating in both categories.

“Achieving Leader status in both Age Estimation and Age Verification reflects that our solutions are built for accurate, scalable, and privacy-first age assurance in high-risk environments,” said Shahid Hanif, Chief Executive Officer of Shufti. “We continue to stay ahead of evolving fraud patterns, including synthetic identities and deepfakes, while keeping verification friction low for legitimate users.”

Why This Recognition Matters Now

Liminal’s buyer survey highlights growing structural pressure in the age assurance market, including rising verification demand, regulatory tightening, and reliance on outdated static models.

Key findings include:

  • 62% of vendors still rely on static systems that do not adapt to new fraud patterns
  • Only 4% use continuous learning-based models
  • 6 in 10 practitioners initiated internal reviews of age assurance methods.
  • Full verification is expected to rise from 48% to 61% (+27%).
  • 44% cite unclear regulation; 39% cite poor user education.

A Multi-Method, Risk-Based Approach To Age Assurance

Shufti addresses these challenges through a unified, risk-based decisioning layer:

  • AI-driven facial age estimation for low-friction entry points.
  • Authoritative database lookups for fast secondary checks.
  • Government ID document verification for higher-assurance use cases.
  • Configurable liveness checks against spoofing, deepfakes, and presentation attacks.

The platform delivers sub-second age estimation, supported by default data minimisation and privacy-by-design architecture. Liminal credits Shufti's in-house platform and full-stack ownership as core strengths.

Independent Certifications And Recognitions

Cited in the Liminal Index Report, Shufti holds:

  • iBeta Level 1 and 2 certifications for liveness detection.
  • KJM recognition in Germany.
  • NIST FATE top-15 placement across Challenge 25 and Child Online Safety metrics.

Independent of the report, Shufti also holds iBeta Level 3 certification and was a 2025 US DHS RIVR top performer.

Liminal also cites Shufti’s privacy-preserving architecture, including on-device age estimation, no-transmission facial processing, and reusable age tokens designed for repeat authentication use cases in privacy-sensitive jurisdictions.

The full 2026 Liminal Index Report is available via Liminal. Read the full Press release via Shufti or contact the Shufti team here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260518793756/en/

Contacts

Media Contact
Aroosa Virk
Brand and Communications Manager
partnership@shuftipro.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye